What was filed
Lupin filed its press release covering unaudited consolidated results for the quarter ended June 30, 2026 (Q1 FY2027), taken on record by the Board on August 6, 2026. The filing reports year-on-year gains across sales, EBITDA and profit, alongside operational detail on the company's key geographies and its U.S. product pipeline.
Where the growth came from
The company said growth was broad-based across geographies. The U.S. — Lupin's largest market at 42% of global sales — led in absolute terms, while India, Other Developed Markets and Emerging Markets each posted double-digit or higher year-on-year gains. Lupin described itself as the 3rd largest generics player in the U.S. by prescriptions (IQVIA Quarter June 2026) and the 8th largest company in the Indian Pharmaceutical Market (IQVIA MAT June 2026). On margins, the filing notes EBITDA margin rose 210 bps year-on-year but eased 410 bps against Q4 FY2026.
Pipeline and balance sheet
During the quarter Lupin received 6 ANDA approvals from the U.S. FDA and launched 3 products in the U.S., taking cumulative ANDA approvals to 350 out of 429 filings. It reported 50 First-to-File filings, including 21 exclusive opportunities. The company also disclosed a net cash position, with net debt of INR -28,308 Mn and a net debt-to-equity ratio of -0.12 as of June 30, 2026.